IP Library Granted Patent US 10,314,739
Granted Patent B2
US 10,314,739 · App. 15/045,797 · Granted Jun 11, 2019

Methods and devices for pain management

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,314,739
App. No.
15/045,797
Granted
Jun 11, 2019
Kind
B2
Abstract

A method in which a location is determined on the skin that is proximate to a sensory nerve that is associated with a painful condition. At least one needle of a cryogenic device is inserted into the location on the skin such that the needle is proximate to the sensory nerve. The device is activated such that the at least one needle creates a cooling zone about the sensory nerve, thereby eliminating or reducing severity of the painful condition.

Claims (29)

1. A method for reducing knee pain experienced by a patient, the method comprising:

determining a location of a treatment zone with reference to a skin surface proximate to a nerve associated with pain of a knee of a leg;

inserting at least one needle of a treatment device through the skin surface and into the treatment zone; and

applying a series of adjacent treatments along a treatment line, the treatment line formed by the series of adjacent treatments being transverse to a length of the nerve, the series of adjacent treatments being applied by:

positioning the at least one needle at a plurality of positions along the treatment line through a plurality of adjacent access sites in the skin surface for applying the series of adjacent treatments that traverse the nerve such that at least one of the plurality of positions where the at least one needle is positioned is adjacent to the nerve; and

activating treatment at each of the plurality of positions such that treatment is applied at each of the plurality of positions along the treatment line and about the nerve, thereby blocking signals along the nerve and eliminating or reducing severity of pain.

2. The method of claim 1 , wherein the pain is associated with osteoarthritis of the knee, and wherein the nerve is an infrapatellar branch of a saphenous nerve, a lateral femoral cutaneous nerve, or an anterior femoral cutaneous nerve.

3. The method of claim 1 , wherein thermal energy is used to treat the nerve.

4. The method of claim 3 , wherein RF is used to create the thermal energy.

5. The method of claim 1 , wherein the treatment is with an injection.

6. The method of claim 5 , wherein the injection is phenol.

7. The method of claim 5 , wherein the injection is ethyl alcohol.

8. The method of claim 1 , wherein each treatment of the series of adjacent treatments generates a corresponding treatment zone and wherein a first generated corresponding treatment zone overlaps a second generated corresponding treatment zone.

9. The method of claim 1 , wherein cryogenic cooling is used to treat the nerve.

10. The method of claim 1 , wherein body landmarks are used to determine the location of the treatment zone.

11. The method of claim 10 , wherein the treatment zone has a superior boundary defined by a midline of a patella of the leg.

12. The method of claim 10 , wherein the treatment zone has an inferior boundary defined by a tibial tubercle of the leg.

13. The method of claim 10 , wherein the treatment zone has a medial boundary defined by a distance lateral to a medial aspect of a patellar tendon of the leg.

14. The method of claim 10 , wherein the treatment zone has a lateral boundary defined by a distance lateral to a lower pole of a patella of the leg.

15. The method of claim 10 , wherein the treatment zone is defined by a medial boundary, a lateral boundary, a superior boundary, and an inferior boundary, wherein the treatment line extends substantially parallel to the medial boundary such that the treatment is applied along the medial boundary between the superior and inferior boundaries.

16. The method of claim 10 , wherein the treatment zone is defined by a medial boundary, a lateral boundary, a superior boundary, and an inferior boundary, and wherein the treatment is applied along the medial and lateral boundaries between the superior and inferior boundaries.

17. The method of claim 1 , wherein the cryogenic device comprises a plurality of needles, and the plurality of needles of the cryogenic device are inserted into the treatment zone.

18. The method of claim 1 , further comprising:

applying a second series of adjacent treatments along a second treatment line, the second treatment line formed by the series of adjacent treatments being transverse to a length of the nerve at a second location, the second series of adjacent treatments being applied by:

positioning the at least one needle at a plurality of positions along the second treatment line through a plurality of adjacent access sites in the skin surface for applying the second series of adjacent treatments that traverse the nerve at the second location such that at least one of the plurality of positions where the at least one needle is positioned is adjacent to the nerve; and

activating treatment at each of the plurality of positions such that treatment is applied at each of the plurality of positions along the second treatment line and about the nerve, thereby blocking signals along the nerve and eliminating or reducing severity of pain.

19. The method of claim 18 , wherein the second treatment line extends substantially parallel to the first treatment line.

20. The method of claim 18 , wherein second treatment line extends substantially perpendicular to the first treatment line.

21. The method of claim 8 , wherein the treatment device comprises a pair of needles and wherein positioning the at least one needle comprises positioning the pair of needles through first and second access sites in the skin surface to generate the first generated corresponding treatment zone and through the second access site and a third access site to generate the second generated corresponding treatment zone such that the first and second generated corresponding treatment zones overlap.

Assignments (6)
RELEASE OF SECURITY INTEREST Recorded Dec 5, 2025
From: JPMORGAN CHASE BANK, N.A.
To: PACIRA CRYOTECH, INC.; PACIRA PHARMACEUTICALS, INC.; PACIRA THERAPEUTICS, INC. (F/K/A FLEXION THERAPEUTICS, INC.)
Reel/Frame 073779/0532 →
TERMINATION AND RELEASE OF SECURITY INTEREST IN PATENTS Recorded Mar 31, 2023
From: JPMORGAN CHASE BANK, N.A.
To: PACIRA CRYOTECH, INC.; PACIRA PHARMACEUTICALS, INC.; PACIRA THERAPEUTICS, INC. (F/K/A FLEXION THERAPEUTICS, INC.)
Reel/Frame 063213/0864 →
CONFIRMATORY GRANT OF SECURITY INTEREST IN UNITED STATES PATENTS Recorded Mar 31, 2023
From: PACIRA CRYOTECH, INC.; PACIRA PHARMACEUTICALS, INC.; PACIRA THERAPEUTICS, INC. (F/K/A FLEXION THERAPEUTICS, INC.)
To: JPMORGAN CHASE BANK, N.A.
Reel/Frame 063214/0108 →
SUPPLEMENTAL CONFIRMATORY GRANT OF SECURITY INTEREST IN UNITED STATES PATENTS Recorded Dec 14, 2021
From: PACIRA CRYOTECH, INC.; PACIRA PHARMACEUTICALS, INC.; FLEXION THERAPEUTICS, INC.
To: JPMORGAN CHASE BANK, N.A.
Reel/Frame 058516/0636 →
CONFIRMATORY ASSIGNMENT Recorded Jul 15, 2019
From: MYOSCIENCE, INC.
To: PACIRA CRYOTECH, INC.
Reel/Frame 049758/0028 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 17, 2016
From: ALLISON, JOHN; RADNOVICH, RICHARD; REYNOLDS, JASON
To: MYOSCIENCE, INC.
Reel/Frame 037755/0715 →
Cited By (7)
US 12,458,424 US 12,458,530 US 12,471,977 US 12,521,161 US 12,611,375 US 12,697,247 US 12,708,422